All Articles

New Molecular Entities and New Biologic License Applications
New Oncology Biosimilars Approved in 2018

New Indications Approved by the FDA in 2018 for Oncology Drugs

By Dalia Buffery, MA, ABD

FDA Updates

2019 Fourth Annual Oncology Guide to New FDA Approvals

Introduction
Oncology Overview
Breast Cancer New Indications
Genitourinary Cancers New Indications
Gynecologic Cancers New Indications
Hematologic Malignancies New Indications
Lung Cancer New Indications
Other Tumor Types New Indications

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

By Yvette Florio Lane

FDA Updates, In the News

Web Exclusives

On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval to the novel antibody-drug conjugate polatuzumab vedotin-piiq (Polivy; Genentech) in combination with bendamustine plus rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least 2 previous therapies. This is the first chemoimmunotherapy regimen approved for use in patients with DLBCL who are ineligible for hematopoietic stem-cell transplantation.

Setting Goals and Celebrating the Accomplishments

By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

Letters from Lillie

June 2019 Vol 10, No 6

We have made such significant strides in the past decade in establishing oncology navigation as a critical element of the cancer care team.

The Importance of Setting Goals, Collecting Data, and Measuring Impact in Patient Navigation Programs

By Dawn Wiatrek, PhD; Nicole L. Erb, BA; Shelby Roberts, MPH

Establishing a Successful Navigation Program

June 2019 Vol 10, No 6

Experts from the American Cancer Society discuss initiatives that demonstrate the value of navigation to patients as well as healthcare systems.

What Is in the Future for Oncology Patient Navigation?

By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

Commentary

June 2019 Vol 10, No 6

A reflection on the beginnings of navigation and a vision of its future.

Why We Need Insurance Coverage for All Americans

By Debra Kelly, RN, BSN, OCN, ONN-CG

Policy & Advocacy

June 2019 Vol 10, No 6

A commentary on the current landscape of healthcare coverage.

An Innovation in Patient Navigation: Background, Methods, and Measures

By Naomi Y. Ko, MD; Sharon Bak, MPH; Christine Gunn, PhD; Kerrie P. Nelson, PhD; Deborah Bowen, PhD; JoHanna Flacks, JD; Samantha Morton, JD; Victoria Parker, PhD; Jane Mendez, MD; Tracy A. Battaglia, MD, MPH

Original Research

June 2019 Vol 10, No 6

The authors present an innovation in patient navigation that integrated 2 care delivery models—patient navigation and legal support for social barriers.

Setting Goals for the Navigation Program, Collecting Data, and Measuring Impact

By Kendra Barber, MHA, RN, OCN; Rachelle Goerke, MSN, BSN, OCN

Establishing a Successful Navigation Program

June 2019 Vol 10, No 6

Learn how to establish goals for your navigation program to ensure its operational success.

Understanding Functions of Somatic and Hereditary Genetic Mutations

By Kate Partynski, MS, LCGC; Lavinia Dobrea, RN, MS, OCN

Biomarkers

June 2019 Vol 10, No 6

Navigators can help patients understand genetic aspects of cancer and its treatment. Here’s how.